Patient Resources

CIALIS Promise™ Program voucher

Offer your patients a FREE TRIAL of 30 tablets of CIALIS for once daily use (2.5 mg or 5 mg) or 3 tablets of CIALIS for use as needed (10 mg or 20 mg).

Our promise: If your patient decides the CIALIS option he tried is not right for him, we promise to pay for another CIALIS option or 3 tablets of another prescription ED medication of your patient’s choice, as prescribed by you.*

*Patients taking CIALIS for once daily use for BPH symptoms only are not eligible for a second trial of an alternative ED treatment.

Download up to 10 vouchers at a time as many times as you'd like.

Download Vouchers

Thank you. Your download is complete.

Your patient can also find vouchers in our brochure or at cialis.com

Your patient can also find vouchers in our brochure
or at cialis.com

CIALIS coverage

Writing a prescription for CIALIS for once daily use for ED+BPH

  • Ensure the appropriate dose/strength, the number of tablets, and the frequency for use (PRN or once daily) are included
  • It may also be beneficial to include the patient’s diagnosis on the prescription
  • Please instruct patients to contact their health plan’s member services to find out if CIALIS for once daily use is covered

Expanded coverage may be available in your area

As of February 2015, more than 210 million lives have commercial formulary access to CIALIS for once daily use with a quantity limit of 30 tablets per 30 days.1†

Based on data from Managed Markets Insight & Technology, LLC, MMIT Analytics as of February 2015. The brand listed is a trademark of its respective owner and is not a trademark of Eli Lilly and Company. The owner of this brand is not affiliated with and does not endorse Eli Lilly and Company or its products.

Help protect your patients from the dangers of counterfeit medication

Some tips you can offer your patients for safer online shopping

  • Only use Internet pharmacies that are accredited through the Verified Internet Pharmacy Practice Sites™ (VIPPS) program2
  • Purchase from US companies only2
    • Even Web sites that claim to be Canadian may purchase medications from other countries around the world, where quality standards vary and the chance of counterfeiting may be much higher
  • Stay away from Web sites that:
    • Don't list a physical address and telephone number in the US2
    • Offer CIALIS at a price that's much lower than the price at the local pharmacy3
    • Sell prescription medications without requiring a prescription from a doctor2
  • Do not purchase generic, "soft tab," or "fast dissolve" CIALIS—there is no generic for CIALIS and CIALIS only comes as an almond-shaped tablet that is swallowed whole4
  • Never respond to an unsolicited e-mail advertisement for CIALIS
    • Eli Lilly and Company, the maker of CIALIS, will never send e-mails to patients unless they have expressly requested such communications and will never attempt to sell CIALIS directly to a patient in any communication

The trademarks listed are the property of their respective owners and are not trademarks of Eli Lilly and Company. The owners of these trademarks are not affiliated with and do not endorse Eli Lilly and Company or its products.

Help your patients learn to identify counterfeit medication

  • Differences in the feel or look of the actual tablets or differences in the packaging may be signs that a medication is counterfeit. Patients should compare their medication with a sample they’ve received from your office or with the image of the original manufacturer's drug below4,5:

Light yellowish, almond-shaped, film-coated tablets:

CIALIS 2.5 mg

Imprinted with "C 2 ½"

CIALIS 2.5 mg pill

CIALIS 5 mg

Imprinted with "C 5"

CIALIS 5 mg pill

Yellow, almond-shaped, film-coated tablets:

CIALIS 10 mg

Imprinted with "C 10"

CIALIS 10 mg pill

CIALIS 20 mg

Imprinted with "C 20"

CIALIS 20 mg pill

Tablets shown not actual size.

  • Patients should pay attention to how the medication tastes and how it makes them feel—an odd taste or unusual symptoms may be signs of a counterfeit5
  • If patients notice any unusual taste or symptoms, they should call you immediately5

Look for signs of a patient using counterfeit medication

If a patient reports that his treatment is not working, or he is experiencing unwanted effects, be sure to ask where he purchased his medication in addition to addressing any symptoms.5

Report any suspicious sales offers or counterfeit medication

If you or your patient suspects that a medication may be counterfeit, contact the Lilly Answers Center at 1‑800‑LILLY‑Rx (1-800-545-5979) and/or the US Food and Drug Administration (FDA) at www.fda.gov/medwatch or 1‑800‑FDA‑1088 (1-800-332-1088).

For more information about counterfeit medication, you can direct your patients to the following online sources:

The Partnership for Safe Medicines

US Food and Drug Administration

Important Safety Information for CIALIS® (tadalafil) tablets

CONTRAINDICATIONS

Nitrates: CIALIS is contraindicated in patients using any form of organic nitrate, either regularly and/or intermittently, as the combination could cause a sudden, unsafe drop in blood pressure.

Hypersensitivity Reactions: CIALIS is contraindicated in patients with a known serious hypersensitivity to CIALIS or ADCIRCA® (tadalafil). Hypersensitivity reactions have been reported, including Stevens-Johnson syndrome and exfoliative dermatitis.

WARNINGS AND PRECAUTIONS

Cardiovascular: Physicians should consider the cardiovascular status of their patients, since there is a degree of cardiac risk associated with sexual activity. Treatments for erectile dysfunction (ED), including CIALIS, should not be used in men for whom sexual activity is inadvisable as a result of their underlying cardiovascular status. Patients who experience symptoms upon initiation of sexual activity should be advised to refrain from further sexual activity and seek immediate medical attention.

Phosphodiesterase 5 (PDE5) inhibitors, including CIALIS, are mild systemic vasodilators. While this effect should not be of consequence in most patients, physicians should consider this potential when prescribing CIALIS.

Patients with left ventricular outflow obstruction (e.g., aortic stenosis and idiopathic hypertrophic subaortic stenosis) can be sensitive to the action of vasodilators, including PDE5 inhibitors.

CIALIS was not studied and is not recommended in patients who have recently suffered a heart attack (within 90 days) or stroke (within 6 months), or patients with uncontrolled hypertension, hypotension, uncontrolled arrhythmias, heart failure (New York Heart Association [NYHA] ≥Class 2 in last 6 months), unstable angina or angina occurring during sexual activity.

Potential Drug Interactions: CIALIS can potentiate the hypotensive effects of alpha-blockers, antihypertensives or substantial amounts of alcohol (≥5 units). CIALIS is not recommended in combination with alpha-blockers for the treatment of benign prostatic hyperplasia (BPH) symptoms because efficacy of the combination has not been adequately studied and due to the risk of blood pressure lowering. Caution is advised when CIALIS is used as a treatment for ED in men taking alpha-blockers. CIALIS for once daily use provides continuous plasma tadalafil levels. Physicians should consider this when evaluating the potential for interactions.

Combination with other PDE5 inhibitors: CIALIS is also marketed as ADCIRCA for the treatment of pulmonary arterial hypertension. Instruct patients not to take CIALIS in combination with ADCIRCA or other PDE5 inhibitors.

Potent inhibitors of CYP3A4: For patients taking potent inhibitors of CYP3A4, dose should be adjusted: CIALIS for use as needed: 10 mg no more than once every 72 hours. CIALIS for once daily use: the maximum recommended dose is 2.5 mg.

Prolonged Erection: There have been rare reports of priapism with this class of compounds. Patients should be advised to seek immediate medical attention should this occur. Use CIALIS with caution in patients who have conditions that might predispose them to priapism.

Vision/Hearing: The following events have been reported in men taking PDE5 inhibitors, including CIALIS: (1) sudden decrease or loss of vision in one or both eyes; (2) sudden decrease or loss of hearing, sometimes with ringing in the ears and dizziness. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors. PDE5 inhibitors, including CIALIS, should be used with caution in patients with a history of non-arteritic anterior ischemic optic neuropathy (NAION), and only when the anticipated benefits outweigh the risks. Patients with a “crowded” optic disc may also be at an increased risk of NAION. If a patient experiences a sudden decrease or loss of vision or hearing, he should stop taking CIALIS and call a healthcare provider right away. Patients with known hereditary degenerative retinal disorders, including retinitis pigmentosa, were not included in the clinical trials, and use in these patients is not recommended.

Specific Populations: Creatinine clearance less than 30 mL/min or on hemodialysis: CIALIS for daily use is not recommended; CIALIS for use as needed—5 mg not more than once every 72 hours. Creatinine clearance 30 to 50 mL/min: For CIALIS for daily use treatment of BPH or ED/BPH, start dosing at 2.5 mg and increase to 5 mg based upon individual response. CIALIS for use as needed—5 mg not more than once per day with maximum dose 10 mg not more than once every 48 hours. Severe hepatic impairment: Use of CIALIS is not recommended. Mild or moderate hepatic impairment: CIALIS has not been extensively evaluated in patients with mild or moderate hepatic impairment; caution is advised if CIALIS is prescribed to these patients. With CIALIS for use as needed, dose should not exceed 10 mg. Additional dose adjustments may be required for patients with other concomitant medications. See full Prescribing Information for complete dosing instructions.

Sexually Transmitted Diseases: The use of CIALIS offers no protection against sexually transmitted diseases. Counseling patients about the protective measures necessary to guard against sexually transmitted diseases, including Human Immunodeficiency Virus (HIV) should be considered.

Consideration of Other Urological Conditions Prior to Initiating Treatment for BPH: Prior to initiating treatment with CIALIS for BPH, consideration should be given to other urological conditions that may cause similar symptoms. In addition, prostate cancer and BPH may coexist.

ADVERSE REACTIONS

Most common adverse reactions (≥2%) with CIALIS for once daily use vs placebo, respectively, include:

In ED (2.5 and 5 mg): headache (3% and 6% vs 5%), dyspepsia (4% and 5% vs 2%), nasal congestion (2% and 2% vs 0%), flushing (1% and 3% vs 1%), and pain in extremity (1% and 2% vs 0%). Back pain (3% and 3% vs 1%) and myalgia (2% and 2% vs 1%) were also reported, sometimes with delayed onset.

In BPH and ED/BPH (5 mg): headache (4.1% vs 2.3%), dyspepsia (2.4% vs 0.2%), nasopharyngitis (2.1% vs 1.6%). Back pain (2.4% vs 1.4%) was also reported, sometimes with delayed onset.

Most common adverse reactions (≥2%) with CIALIS for use as needed in ED (5 mg, 10 mg, and 20 mg) vs placebo, respectively, include: headache (11%, 11%, and 15% vs 5%), dyspepsia (4%, 8%, and 10% vs 1%), nasal congestion (2%, 3%, and 3% vs 1%), flushing (2%, 3%, and 3% vs 1%), and pain in limb (1%, 3%, and 3% vs 1%). Back pain (3%, 5%, and 6% vs 3%) and myalgia (1%, 4%, and 3% vs 1%) were also reported, sometimes with delayed onset.

For more complete information, please see full Prescribing Information and Patient Information.

TD HCP ISI 07MAY2014

References

  1. Data on file. Lilly USA, LLC. CIA20150211A.
  2. National Association of Boards of Pharmacy. Buying medicine online. http://www.nabp.net/programs/consumer-protection/buying-medicine-online/. Accessed June 14, 2012.
  3. US Food and Drug Administration Consumer Health Information. The possible dangers of buying medicines over the Internet. http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/UCM204943.pdf. Accessed June 13, 2012.
  4. Cialis [package insert]. Indianapolis, IN: Eli Lilly and Company; 2014.
  5. The Partnership for Safe Medicines. S.A.F.E. D.R.U.G.: an 8-step checklist for medicine safety. http://www.safemedicines.org/consumer/SAFEDRUG.pdf. Accessed June 14, 2012.